These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 11366351

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The choice of HIV protease inhibitor: indinavir is currently the best option.
    Prescrire Int; 1999 Apr; 8(40):55-60. PubMed ID: 10848067
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy.
    Condra JH, Petropoulos CJ, Ziermann R, Schleif WA, Shivaprakash M, Emini EA.
    J Infect Dis; 2000 Sep; 182(3):758-65. PubMed ID: 10950769
    [Abstract] [Full Text] [Related]

  • 6. Double protease inhibitor regimens with amprenavir show promise.
    AIDS Patient Care STDS; 1998 Apr; 12(4):317-8. PubMed ID: 11361962
    [No Abstract] [Full Text] [Related]

  • 7. [Diabetes and hyperglycemia in patients under treatment for HIV infection with the protease inhibitors indavir, ritonavir, saquinavir as well as nelfinavir (in development, but not yet released].
    Pharm Unserer Zeit; 1997 Dec; 26(6):317. PubMed ID: 9513575
    [No Abstract] [Full Text] [Related]

  • 8. Drug interactions and protease inhibitor therapy in the treatment of HIV/AIDS.
    Klaus BD, Grodesky MJ.
    Nurse Pract; 1998 Feb; 23(2):102-4, 106. PubMed ID: 9513221
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A patient's guide to protease inhibitors.
    Elperin A, Sax P.
    AIDS Clin Care; 1996 Oct; 8(10):83-4. PubMed ID: 11363988
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.
    Justesen US, Fox Z, Pedersen C, Cahn P, Gerstoft J, Clumeck N, Losso M, Peters B, Obel N, Castagna A, Dragsted UB, Lundgren JD, MaxCmin1 and 2 trial groups.
    Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):339-44. PubMed ID: 17910618
    [Abstract] [Full Text] [Related]

  • 16. Hyperlipidemia associated with the use of protease inhibitors.
    Smith JH, Martin GJ, Decker CF.
    Clin Infect Dis; 2000 Jul; 31(1):207-8. PubMed ID: 10913432
    [No Abstract] [Full Text] [Related]

  • 17. HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy.
    Craig C, Race E, Sheldon J, Whittaker L, Gilbert S, Moffatt A, Rose J, Dissanayeke S, Chirn GW, Duncan IB, Cammack N.
    AIDS; 1998 Sep 10; 12(13):1611-8. PubMed ID: 9764779
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Peptidomimetic inhibitors of HIV protease.
    Randolph JT, DeGoey DA.
    Curr Top Med Chem; 2004 Sep 10; 4(10):1079-95. PubMed ID: 15193140
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.